These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 25519996)

  • 21. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
    Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
    Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncological Outcome of Cytoreductive Radical Prostatectomy in Prostate Cancer Patients With Bone Oligometastases.
    Lan T; Chen Y; Su Q; Ye J
    Urology; 2019 Sep; 131():166-175. PubMed ID: 31181273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?
    Mathieu R; Korn SM; Bensalah K; Kramer G; Shariat SF
    World J Urol; 2017 Apr; 35(4):567-577. PubMed ID: 27502935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of adjuvant radiotherapy and androgen deprivation therapy after radical prostatectomy in high risk prostate cancer patients - results from retrospective analysis.
    Omrcen T; Hrepic D; Boraska Jelavic T; Vrdoljak E
    J BUON; 2015; 20(4):1061-7. PubMed ID: 26416057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Radical cancer surgery of renal cell and prostate carcinoma with hematogenous metastasis: benefits].
    Heidenreich A; Pfister D; Porres D
    Urologe A; 2014 Jun; 53(6):823-31. PubMed ID: 24824471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment.
    Bantis A; Zissimopoulos A; Kalaitzis C; Giannakopoulos S; Sountoulides P; Parmenopoulou V; Agelonidou E; Touloupidis S
    Hell J Nucl Med; 2008; 11(1):21-5. PubMed ID: 18392222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics.
    Sood A; Zhang LT; Keeley J; Butaney M; Stricker M; Andrews JR; Grauer R; Peabody JO; Rogers CG; Menon M; Abdollah F
    Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):58-64. PubMed ID: 35794359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
    Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
    Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
    Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
    BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The oncologic results of cryoablation in prostate cancer patients with bone metastases.
    Si T; Guo Z; Yang X; Zhang W; Xing W
    Int J Hyperthermia; 2018 Nov; 34(7):1044-1048. PubMed ID: 28974120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy.
    Yang DD; Muralidhar V; Mahal BA; Nezolosky MD; Labe SA; Vastola ME; Boldbaatar N; King MT; Martin NE; Orio PF; Choueiri TK; Trinh QD; Den RB; Spratt DE; Hoffman KE; Feng FY; Nguyen PL
    Urol Oncol; 2017 Sep; 35(9):542.e25-542.e32. PubMed ID: 28533151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.